Nature Medicine | A Phase 1 Clinical Trial of the Structure-Based mRNA Vaccine mRNA-1215 in Healthy Adults

This study provides critical early clinical data for Nipah virus vaccine development, supporting further evaluation of mRNA-1215 in high-risk populations and offering a reference for effective immunization strategies against potential outbreaks.

 

Literature Overview

The article titled 'A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial,' published in the journal Nature Medicine, systematically investigates the first-in-human safety and immunogenicity of the mRNA vaccine mRNA-1215 targeting the highly pathogenic zoonotic Nipah virus (NiV). Using a dose-escalation design, the study evaluated tolerability and immune responses across a dose range of 10–100 μg in 40 healthy adults. Results demonstrated that the vaccine was generally safe, with adverse events predominantly mild to moderate, and all dose groups induced robust binding and neutralizing antibody responses that persisted for at least one year. These findings lay the foundation for further clinical development in populations living in endemic areas.

Background Knowledge

Nipah virus (NiV) is a paramyxovirus with pandemic potential, capable of causing severe encephalitis and respiratory disease, with case fatality rates as high as 40–75%. Currently, no vaccines or therapeutics are approved. Fruit bats of the genus Pteropus serve as the natural reservoir, and the virus spreads via intermediate hosts (e.g., pigs) or through human-to-human transmission, with repeated outbreaks reported in Bangladesh, India, and Malaysia. The World Health Organization (WHO) has classified NiV as a priority pathogen, highlighting the urgent need for rapidly deployable vaccine strategies. Most existing vaccine candidates focus on the viral G attachment protein, which exhibits antigenic variability across strains. In contrast, the F fusion protein is more conserved among henipaviruses, and its prefusion conformation (Pre-F) elicits stronger neutralizing antibodies. Therefore, vaccines targeting both Pre-F and G antigens may offer broader protection. The mRNA platform offers advantages of rapid development and flexible design, making it well-suited for responding to emerging outbreaks. This study leverages this approach by developing mRNA-1215, encoding a Pre-F/G chimeric protein from the NiV(M) strain, and evaluates its feasibility in humans.

 

 

Research Methods and Experiments

The study employed a single-center, open-label, dose-escalation phase 1 trial design, enrolling 40 healthy adults divided into four dose groups (10, 25, 50, and 100 μg; n=10 per group), who received two intramuscular doses of mRNA-1215 administered four weeks apart. The primary endpoints were safety and tolerability, assessed by recording local and systemic reactogenicity within 7 days post-vaccination, adverse events (AEs) within 28 days, and serious adverse events (SAEs) through study completion. Secondary endpoints included immunogenicity, measured by anti-Pre-F and anti-G binding and neutralizing antibody titers. Exploratory analyses evaluated B-cell and T-cell immune responses and cross-reactivity against NiV(B) and Hendra virus (HeV). Antibody responses were quantified using ELISA and pseudovirus neutralization assays (PVNA), T-cell phenotypes were analyzed by flow cytometry, and memory B cells were assessed using B-cell probe binding assays.

Key Conclusions and Perspectives

• The vaccine was generally safe, with the most common local and systemic AEs being mild injection-site pain (83%) and mild fatigue (40%), respectively. No SAEs were reported, indicating that mRNA-1215 is well tolerated.
• Anti-Pre-F and anti-G binding antibodies were detectable two weeks after the first dose in all groups, increased significantly after the booster, and remained at high levels for up to one year, suggesting that the mRNA vaccine induces durable humoral immunity.
• Neutralizing antibodies were detectable two weeks after priming, peaked after boosting, and reached comparable levels across all dose groups, indicating that even a low dose of 10 μg can elicit effective neutralizing responses.
• The vaccine induced CD4+ T-cell responses against both Pre-F and G, predominantly of the TH1 and Tfh subtypes, and CD8+ T-cell responses were detectable in groups receiving doses >10 μg, demonstrating effective activation of cellular immunity.
• Antibodies and memory B cells induced by the vaccine showed cross-reactivity against NiV(B) and HeV, with neutralizing antibodies persisting up to 56 weeks, suggesting the potential for broad protection against multiple henipaviruses.

Research Significance and Prospects

This study represents the first human validation of a structure-based mRNA vaccine against NiV, offering a strong candidate for responding to NiV outbreaks. Its ability to rapidly induce durable immune responses makes it suitable for emergency use during outbreaks. Given the impracticality of conducting large-scale efficacy trials, future approval may rely on immune bridging or protective data from animal models. The vaccine’s broad-spectrum potential is particularly important, as NiV(B) outbreaks occur nearly annually in Bangladesh, and HeV poses a threat in Australia. Thus, mRNA-1215 may serve as a prototype for pan-henipavirus vaccines. Moreover, this study confirms the superiority of the Pre-F/G dual-antigen strategy, providing a template for vaccine design against other paramyxoviruses.

 

 

Conclusion

This study marks a significant step forward in advancing mRNA vaccines against Nipah virus from concept to clinical application. mRNA-1215 demonstrated favorable safety and potent, durable immunogenicity in healthy adults, while also eliciting cross-protective immune responses, providing a critical tool to combat outbreaks of NiV and related viruses. The structure-guided Pre-F/G dual-antigen strategy not only enhances the breadth and strength of immune responses but also establishes a replicable platform for future vaccine development against highly pathogenic RNA viruses. Although further validation in populations in endemic areas and high-risk groups is needed, the vaccine already shows great promise as a rapid-response measure during outbreaks. From laboratory to field deployment, mRNA-1215 exemplifies the successful translation of cutting-edge vaccine technology into practical public health solutions, with the potential to significantly enhance global preparedness against high-consequence pathogens. Future research should focus on characterizing immune responses in high-risk populations, optimizing booster strategies, and evaluating real-world protective efficacy.

 

Aurélie Ploquin, Rosemarie D Mason, LaSonji A Holman, Lesia K Dropulic, and The VRC 322 study team. A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial. Nature Medicine.